Bristol-Myers Squibb BMY Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 281.3%-15.8pp | 297.1%-10.4pp | 307.5%-8.1pp | 315.6%+9.8pp | |
| Net margin | 48.7%+110pp | -61.5%-131pp | 69.8%+14.5pp | 55.3%+78.1pp | |
| Returns | |||||
| Return on equity | 134.4%+257pp | -123%-224pp | 101.1%+26.0pp | 75.1%+94.6pp | |
| Return on invested capital | 40.2%+85.9pp | -45.6%-101pp | 55%+9.9pp | 45%+50.2pp | |
| Efficiency | |||||
| Asset turnover | 2×0.0× | 2×+0.1× | 1.9×+0.1× | 1.8×+0.3× | |
| Liquidity | |||||
| Current ratio | 5×+0.2× | 4.8×-0.7× | 5.4×0.0× | 5.4×-0.7× | |
| Leverage | |||||
| Debt-to-equity | 10.9×-1.6× | 12.5×+7.3× | 5.2×-0.1× | 5.3×+0.3× | |
| Net debt / EBITDA | 11×-65.2× | 76.2×+69.5× | 6.6×-0.6× | 7.2×-10.2× | |
| Valuation | |||||
| Market capitalization | $421.42B+1.9% | $413.46B-18.3% | $505.78B-18.9% | $623.91B+11.8% | |
| Price / earnings | 73.4×— | —— | 64.5×-32.1× | 96.5×— | |
| Price / sales | 8.8×0.0× | 8.8×-2.4× | 11.2×-2.2× | 13.3×+0.9× | |
| Price / book | 23.5×-1.2× | 24.7×+8.2× | 16.5×-3.0× | 19.5×+4.4× | |
| EV / EBITDA | 42.7×-226× | 268.2×+234× | 33.9×-8.0× | 41.8×-46.7× | |
| Dividend yield | 19.2%+0.3pp | 18.8%+3.7pp | 15.1%+3.4pp | 11.7%-0.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Bristol-Myers Squibb's ratios come from?
- Every ratio is computed from Bristol-Myers Squibb's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
